Retatrutide is the drug the whole obesity field has been waiting on, and over the weekend it delivered again.
Lilly reported positive topline results from TRIUMPH 2 in type 2 diabetes and TRIUMPH 3 in cardiovascular disease, two pivotal Phase 3 trials we have carried on our catalyst calendar for months. These are the readouts that broaden retatrutide’s story from weight loss alone to the metabolic and cardiovascular outcomes that drive the largest markets and the best reimbursement. Combined with TRIUMPH 1’s 28.3% weight loss in obesity—the highest ever demonstrated in a Phase 3—retatrutide now has three positive pivotal trials across the three indications that matter most: obesity, diabetes, and cardiovascular disease.
This is the asset behind the projections that Lilly’s metabolic franchise becomes the biggest blockbuster ever, topping $70 billion by the early 2030s. With the TRIUMPH program delivering across settings, those projections look less like optimism and more like a base case.
For everyone chasing Lilly in obesity—from Novo defending the franchise it created, to Pfizer rebuilding from scratch—the target just moved further away. Section 232 tariffs land Friday. Otsuka won its ADHD approval. Sanofi dropped a drug it once counted on. And J&J sharpened its myeloma survival case.
Three Pivotal Wins: The Most Comprehensive Obesity Drug Ever Tested
What Happened: Lilly reported positive topline results from TRIUMPH 2 (type 2 diabetes) and TRIUMPH 3 (cardiovascular disease), adding to the TRIUMPH 1 obesity win reported earlier this year.
Why the Triple Agonist Mechanism Matters
Retatrutide is a first in class triple hormone receptor agonist that simultaneously targets GIP, GLP 1, and glucagon. Every other approved or near approved obesity drug hits one or two of those receptors. Zepbound (tirzepatide) targets GIP and GLP 1. Wegovy (semaglutide) targets GLP 1 alone. Retatrutide adds the glucagon receptor, and that third lever is the leading explanation for the approximately 28% weight loss it showed in Phase 2—substantially more than any competitor.
The glucagon component increases energy expenditure and fat oxidation on top of the appetite suppression that GLP 1 and GIP provide. In simple terms, the drug reduces how much a patient eats (GLP 1 and GIP) while simultaneously increasing how much energy the body burns at rest (glucagon). That combination produces the highest weight loss in the class because it attacks the caloric balance from both sides.
What TRIUMPH 2 and TRIUMPH 3 Add to the Story
TRIUMPH 1 established retatrutide in obesity with 28.3% weight loss. That was the efficacy statement. TRIUMPH 2 and TRIUMPH 3 expand the drug into the indications that determine how large the franchise becomes.
TRIUMPH 2 (type 2 diabetes): The trial met primary and key secondary endpoints for HbA1c reduction and weight loss. This is essential because a T2D label roughly doubles the addressable patient population. The approximately 40 million American adults with clinical obesity overlap significantly with the approximately 37 million with type 2 diabetes, but the labels are separate, and each opens a different prescribing pathway. A drug approved in both obesity and diabetes can be prescribed by endocrinologists, primary care physicians, and diabetologists, each reaching different patient populations.
TRIUMPH 3 (cardiovascular disease): The trial hit its endpoints in cardiovascular risk reduction. This is the indication that drives the strongest payer coverage and the highest willingness to reimburse. Cardiovascular outcomes trials are the gold standard for demonstrating that a metabolic drug does more than help patients lose weight—it actually reduces heart attacks, strokes, and cardiovascular death. That evidence transforms a drug from a lifestyle product into a medically necessary treatment, which changes every payer conversation.
With three positive pivotal trials, retatrutide now has the most comprehensive Phase 3 evidence package of any metabolic disease drug in development or on the market. No competitor has demonstrated this combination of weight loss magnitude, diabetes efficacy, and cardiovascular benefit in a single molecule.
What This Means for the $70 Billion Projection
Evaluate projects Lilly’s metabolic franchise—spanning Foundayo, Zepbound, and retatrutide—becomes the biggest blockbuster franchise in pharmaceutical history, topping $70 billion by the early 2030s. The TRIUMPH readouts move that projection from aggressive forecast toward base case.
Here is the logic. Retatrutide at 28.3% weight loss owns the top of the efficacy curve. Zepbound at approximately 22% owns the established injectable market. Foundayo at approximately 12% owns the oral convenience market. Together they give Lilly a three tier portfolio that offers physicians a clinical decision tree for every type of patient:
Start with Foundayo for the patient who wants a pill and needs moderate weight loss. Escalate to Zepbound for the patient who needs more aggressive treatment and is comfortable with injections. Move to retatrutide when the patient needs the most potent pharmacological option short of surgery—a drug that produces weight loss matching bariatric surgery results while simultaneously improving diabetes control and reducing cardiovascular risk.
No other company has anything close to this portfolio breadth. Novo has two versions of semaglutide (oral and injectable) that deliver the same mechanism at the same approximate efficacy level. Pfizer is rebuilding from scratch after danuglipron failed. The next generation challengers—amylin combinations, muscle preserving agents—are years behind. Retatrutide’s triple pivotal success widens a gap that was already significant.
The 2027 launch that analysts have penciled in now looks increasingly realistic. With three positive pivotal trials in hand, Lilly has the data package to support an NDA covering obesity, diabetes, and cardiovascular risk reduction. The December 7 Investment Community Meeting will be the venue where Lilly explains how it plans to manufacture, price, and launch the most commercially ambitious drug in the history of the industry.
Our Pro brief analyzes what the three pivotal wins mean for the $70B projection and for everyone trying to catch Lilly. [Details below.]
Section 232 Tariffs Land Friday
The Section 232 pharmaceutical tariffs take effect for large companies this Friday, July 31. This has been on our calendar for months, and it is now four days away.
The Trade Pressure Is Stacking
The Section 232 tariffs arrive on top of the generic drug tariffs Trump announced last week for 2028. So the entire pharmaceutical supply chain is being pushed toward domestic production simultaneously: large branded manufacturers face the Section 232 levies starting Friday, and the generic supply chain faces its own countdown.
The tariffs are levied on national security grounds, targeting the concentration of drug and ingredient production overseas. For large branded manufacturers, the immediate exposure is the imported finished products and active pharmaceutical ingredients in their supply chains. The levies are designed to make domestic production relatively more attractive by raising the cost of imports.
What We Are Watching This Week
Onshoring announcements. Companies have been front running this for months. Lilly, Regeneron, Hikma, and others have committed to U.S. manufacturing investments. BeOne Medicines announced a $300 million expansion of its Princeton West manufacturing and R&D center in New Jersey over the weekend, bringing its total U.S. investment past $1 billion. Expect more announcements timed to the deadline.
Earnings commentary. The large caps still reporting this week will be asked directly about tariff exposure. Their answers will reveal who is genuinely hedged through existing domestic capacity and who faces margin pressure from import costs they cannot quickly redirect.
Supply chain signals. The real test is not the announcements but the operational reality. Manufacturing cannot be moved in a week. Companies with heavy overseas production footprints will absorb the tariff cost in the near term and make relocation decisions over the next one to three years. The Section 232 deadline is the start of that adjustment process, not the conclusion.
The September 29 deadline for all other companies (smaller pharma) follows two months later. The dual timeline gives the industry a staggered implementation that hits the largest companies first and smaller ones later, creating a competitive dynamic where large companies absorb costs that smaller competitors do not yet face.
Otsuka Landed Its ADHD Approval
What Happened: The FDA approved Otsuka’s Simtriyo (centanafadine), a once daily extended release capsule for ADHD.
A Non Stimulant Option in a Market That Needs More of Them
ADHD is a large and durable market, and the treatment landscape has been dominated by stimulants (methylphenidate, amphetamine salts) for decades. Stimulants work well for most patients, but they carry concerns about supply (shortages have been persistent in recent years), misuse potential, and side effects that make some patients and physicians prefer alternatives.
Simtriyo is a non stimulant option, which gives it a distinct positioning. The non stimulant ADHD market already includes Strattera (atomoxetine) and Qelbree (viloxazine), but more options in this category serve a genuine clinical need. Patients who cannot tolerate stimulants, who have contraindications, or who prefer to avoid controlled substances now have another choice.
For Otsuka, better known for its psychiatric franchise anchored by Abilify and Rexulti (whose partnership with Lundbeck is unwinding after 25 years, as we covered), a fresh ADHD approval adds a growth driver in central nervous system disease. It is one of the few genuinely positive results in a neuropsychiatry field that has been punishing this year—Neumora dropped navacaprant, Merck killed its Alzheimer’s program, GSK walked from Alector, and Biogen’s tau data validated the science but missed the primary endpoint.
Sanofi Dropped a Drug It Once Counted On
What Happened: Sanofi discontinued clinical development of amlitelimab, an OX40 ligand antibody, in moderate to severe atopic dermatitis.
The Pressure on Sanofi’s Pipeline Is Building
Amlitelimab was not a minor program. Sanofi had positioned the drug as a future immunology growth driver, part of its answer to the eventual decline of Dupixent—the mega blockbuster it shares with Regeneron that faces a patent cliff in the coming years. Dropping it in atopic dermatitis, one of the largest immunology markets, removes a piece of the post Dupixent plan at exactly the wrong moment.
Stack up what has happened to Sanofi this year. Riliprubart failed Phase 3 in CIDP. The EU opened an antitrust investigation over Sanofi’s flu vaccine marketing. The FDA issued a warning letter at the Genzyme manufacturing site in Ireland over Altuviiio production violations. And now amlitelimab is discontinued.
Individually, each of these is the kind of setback every large pharma absorbs. Together, they form a pattern that raises genuine questions about whether Sanofi’s pipeline can generate the growth needed to offset the Dupixent cliff and justify the company’s strategy. Dupixent generated $14 billion in 2025, and AbbVie’s $10.9 billion acquisition of Apogee (zumilokibart, two to four injections per year versus Dupixent’s 26) is positioning a direct competitor to capture share. Sanofi needs its pipeline to deliver, and the pipeline keeps delivering disappointments instead.
The company is not in crisis. It retains a strong commercial base, real assets in vaccines and rare disease, and the Dupixent franchise is still generating enormous revenue. But the margin for error is shrinking, and the narrative has shifted from “Sanofi is executing well” to “Sanofi needs a win.” The remaining immunology and rare disease readouts carry more weight now than they did three months ago.
J&J Sharpened Its Myeloma Survival Case
What Happened: J&J reported positive Phase 3 data showing a dual bispecific antibody regimen sharply improved survival in relapsed or refractory multiple myeloma, building on the MonumenTAL 6 readout from last week.
Why This Matters: The fuller data reinforce the numbers we covered Friday: 89% improvement in progression free survival and a 62% overall survival benefit with the Tecvayli plus Talvey combination in earlier lines of myeloma treatment. Combining two bispecific antibodies that hit different targets—BCMA (Tecvayli) and GPRC5D (Talvey)—is an aggressive treatment strategy, and the survival data justify the approach.
For J&J, the myeloma franchise is now the best performing part of its oncology portfolio, arriving at a moment when the broader oncology business disappointed in Q2 earnings. The bispecific combination positions J&J as the leading player in what may become the standard approach to earlier line myeloma treatment, ahead of single agent bispecifics and competing with the CAR T approaches from Lilly (Kelonia) and Gilead (anito cel from Arcellx).
Quick Hits
Merck set out early access plans for alimatravir, its investigational once monthly oral HIV PrEP, signing voluntary licensing deals to speed availability in low and middle income countries if approved. A once monthly oral prevention option (versus Gilead’s daily Truvada or Descovy) would be transformational for global HIV prevention, particularly in regions where daily adherence and access to injectable options are challenging.
BeOne Medicines announced a $300 million expansion of its Princeton West manufacturing and R&D center in New Jersey, bringing its total U.S. investment past $1 billion. The timing—four days before Section 232 tariffs—reinforces the pattern of companies front running the tariff deadline with domestic manufacturing commitments.
China out licensing is outpacing last year’s record, a PharmTech expert panel reported. Peptide manufacturing is expanding beyond GLP 1 into cardiovascular and CNS applications, and there is a push to onshore bioconjugate manufacturing to reduce reliance on Chinese production. The dual dynamic—more Chinese science flowing out while the industry tries to reduce its manufacturing dependence on China—captures the fundamental tension of the year.
Strategic Themes
1. Three Pivotal Wins Make Retatrutide the Most Validated Late Stage Drug in the Industry
Obesity. Diabetes. Cardiovascular disease. Three indications confirmed at the pivotal level for a single molecule that produces the highest weight loss in the class. The $70 billion franchise projection that sounded aggressive six months ago now has three Phase 3 wins supporting it. Retatrutide does not just extend Lilly’s lead in obesity. It redefines what a metabolic disease franchise looks like: a single drug that treats the upstream cause (obesity) and the downstream consequences (diabetes, cardiovascular disease) simultaneously.
2. Section 232 Tariffs Landing Friday Is the First Real Test of Whether Trade Policy Reshapes Pharma Manufacturing
Announcements and commitments are one thing. Tariffs taking effect are another. Friday is when the cost of importing pharmaceutical products from overseas rises for large companies, and the industry’s response—onshoring acceleration, margin absorption, pricing adjustments—will show whether the policy achieves its goal of shifting production or simply raises costs that get passed through the system.
3. Sanofi Needs a Pipeline Win Before the Dupixent Cliff Arrives
Riliprubart failed. Amlitelimab discontinued. Antitrust investigation opened. Warning letter received. Each individual setback is manageable. The accumulation is not. Sanofi’s growth story depends on pipeline execution, and the pipeline is underperforming at the worst possible time. AbbVie’s zumilokibart is positioning to challenge Dupixent. The patent cliff is approaching. Every remaining readout carries more weight than it did a quarter ago.
4. J&J’s Myeloma Data Are the Strongest Argument Its Oncology Franchise Has Made All Quarter
89% PFS improvement. 62% OS benefit. In earlier treatment lines. The Q2 oncology sales miss raised questions about J&J’s competitive positioning. The MonumenTAL 6 data answer those questions with numbers that could change how myeloma is treated. Sometimes the franchise’s best data is ahead of the current quarter’s revenue, and that appears to be the case here.
Frequently Asked Questions
What did retatrutide show?
Positive topline results in TRIUMPH 2 (type 2 diabetes) and TRIUMPH 3 (cardiovascular disease), adding to TRIUMPH 1 (28.3% weight loss in obesity). Three pivotal wins across three indications for a first in class triple agonist (GIP, GLP 1, glucagon). Analysts project a 2027 launch and $70 billion plus franchise.
When do Section 232 tariffs hit?
Friday, July 31, for large companies. September 29 for all others. They arrive on top of the 2028 generic drug tariffs announced last week, stacking trade pressure on both branded and generic imports.
What is Simtriyo?
Otsuka’s centanafadine, a once daily non stimulant ADHD treatment. One of the few positive neuropsychiatry results of the year. Gives patients an alternative to stimulants in a market with supply concerns and misuse risk.
Why did Sanofi drop amlitelimab?
The OX40 ligand antibody was discontinued in atopic dermatitis. It adds to a difficult year that includes the riliprubart failure, EU antitrust investigation, FDA manufacturing warning letter, and approaching Dupixent patent cliff. Sanofi’s pipeline needs a win.
What are J&J’s myeloma numbers?
Tecvayli plus Talvey showed 89% PFS improvement and 62% OS benefit in earlier line myeloma (MonumenTAL 6). A bispecific combination targeting two different antigens. Numbers that could change how earlier myeloma is treated.
How many TRIUMPH trials remain?
Five more beyond the three that have reported (TRIUMPH 1 obesity, TRIUMPH 2 T2D, TRIUMPH 3 CV). The remaining trials cover sleep apnea, chronic low back pain, liver disease, and other metabolic indications.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Retatrutide Is Now De Risked Across Three Settings. We analyze what three pivotal wins mean for the $70B franchise projection, assess whether the 2027 launch timeline is realistic given manufacturing and regulatory considerations, and evaluate how wide Lilly’s lead has become over every competitor in the obesity space.
Section 232 Tariffs Hit Friday. We map which companies face the most exposure based on overseas manufacturing footprints, identify what to watch in the earnings commentary as the deadline lands, and assess whether the tariffs will actually shift production or simply raise costs.
Sanofi Keeps Stumbling. We compile the accumulating pipeline pressure, assess whether the growth story still holds under the weight of multiple setbacks, and identify which remaining readouts Sanofi needs to hit to change the narrative before the Dupixent cliff arrives.
Plus: J&J myeloma franchise implications, Otsuka ADHD launch positioning, Merck once monthly HIV PrEP early access, BeOne onshoring expansion, China out licensing trends, and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
